PRO 045

Drug Profile

PRO 045

Alternative Names: BMN-045; PRO045

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Prosensa
  • Developer BioMarin Nederland
  • Class Antisense oligonucleotides
  • Mechanism of Action Antisense RNA modulators; Dystrophin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 31 May 2016 Discontinued - Phase-II for Duchenne muscular dystrophy (In adolescents, In children) in Netherlands, United Kingdom, Italy, France, Belgium (SC)
  • 28 Apr 2015 Prosensa Therapeutics is now called BioMarin Nederland
  • 30 Mar 2015 Phase-II clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Belgium, France, Italy, United Kingdom and Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top